Literature DB >> 19131181

Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma.

Giuseppe Sanguineti1, Joseph Califano, Edward Stafford, Jana Fox, Wayne Koch, Ralph Tufano, Maria Pia Sormani, Arlene Forastiere.   

Abstract

PURPOSE: To assess the risk of ipsilateral subclinical neck nodal involvement for early T-stage/node-positive oropharyngeal squamous cell carcinoma. METHODS AND MATERIALS: Patients undergoing multilevel upfront neck dissection (ND) at Johns Hopkins Hospital within the last 10 years for early clinical T-stage (cT1-2) node-positive (cN+) oropharyngeal squamous cell carcinoma were identified. Pathologic involvement of Levels IB-V was determined. For each nodal level, the negative predictive value of imaging results was computed by using sensitivity/specificity data for computed tomography (CT). This was used to calculate 1 - negative predictive value, or the risk that a negative level on CT harbors subclinical disease.
RESULTS: One hundred three patients met the criteria. Radical ND was performed in 14.6%; modified radical ND, in 70.9%; and selective ND, in 14.6%. Pathologic positivity rates were 9.5%, 91.3%, 40.8%, 18.0%, and 3.3% for Levels IB-V, respectively. Risks of subclinical disease despite negative CT imaging results were calculated as 3.1%, 76.3%, 17.5%, 6.3%, and 1.0% for Levels IB-V, respectively.
CONCLUSIONS: Levels IB and V are at very low (<5%) risk of involvement, even with ipsilateral to pathologically proven neck disease; this can guide radiation planning. Levels II and III should be included in high-risk volumes regardless of imaging results, and Level IV should be included within the lowest risk volume.

Entities:  

Mesh:

Year:  2009        PMID: 19131181     DOI: 10.1016/j.ijrobp.2008.10.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Temporal characterization of lymphatic metastasis in an orthotopic mouse model of oral cancer.

Authors:  Peter Szaniszlo; Susan M Fennewald; Suimin Qiu; Carla Kantara; Tuya Shilagard; Gracie Vargas; Vicente A Resto
Journal:  Head Neck       Date:  2014-01-27       Impact factor: 3.147

2.  Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy.

Authors:  John Cuaron; Shyam Rao; Suzanne Wolden; Michael Zelefsky; Karen Schupak; Borys Mychalczak; Nancy Lee
Journal:  Head Neck       Date:  2015-07-06       Impact factor: 3.147

3.  Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.

Authors:  Moses Tam; Nadeem Riaz; Danita Kannarunimit; Angela P Peña; Karen D Schupak; Daphna Y Gelblum; Suzanne L Wolden; Shyam Rao; Nancy Y Lee
Journal:  Am J Clin Oncol       Date:  2015-08       Impact factor: 2.339

4.  Role of positron emission tomography in the treatment of occult disease in head-and-neck cancer: a modeling approach.

Authors:  Mark H Phillips; Wade P Smith; Upendra Parvathaneni; George E Laramore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-25       Impact factor: 7.038

5.  HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V.

Authors:  Giuseppe Sanguineti; Sara Pai; Harold Agbahiwe; Francesco Ricchetti; William Westra; Maria Pia Sormani; Stefania Clemente; Joseph Califano
Journal:  Acta Oncol       Date:  2013-11-25       Impact factor: 4.089

6.  Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group.

Authors:  Anna Merlotti; Daniela Alterio; Riccardo Vigna-Taglianti; Alessandro Muraglia; Luciana Lastrucci; Roberto Manzo; Giuseppina Gambaro; Orietta Caspiani; Francesco Miccichè; Francesco Deodato; Stefano Pergolizzi; Pierfrancesco Franco; Renzo Corvò; Elvio G Russi; Giuseppe Sanguineti
Journal:  Radiat Oncol       Date:  2014-12-29       Impact factor: 3.481

7.  Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.

Authors:  Michael F Gensheimer; Jay J Liao; Adam S Garden; George E Laramore; Upendra Parvathaneni
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

8.  An elective radiation dose of 46 Gy is feasible in nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: A long-term follow-up result.

Authors:  Tsung-Min Hung; Kang-Hsing Fan; Eric Yen-Chao Chen; Chien-Yu Lin; Chung-Jan Kang; Shiang-Fu Huang; Chun-Ta Liao; Shu-Hang Ng; Hung-Ming Wang; Joseph Tung-Chieh Chang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

9.  A hidden Markov model for lymphatic tumor progression in the head and neck.

Authors:  Roman Ludwig; Bertrand Pouymayou; Panagiotis Balermpas; Jan Unkelbach
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

10.  Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.

Authors:  Enrique Chajon; Caroline Lafond; Guillaume Louvel; Joël Castelli; Danièle Williaume; Olivier Henry; Franck Jégoux; Elodie Vauléon; Jean-Pierre Manens; Elisabeth Le Prisé; Renaud de Crevoisier
Journal:  Radiat Oncol       Date:  2013-05-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.